Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chiome BioscienceTSE:4583 -2.02%50 Days Payable is 80.91 as of Jun. 2026, which is 56% above its 10-year median of 51.95. GuruFocus rates TSE:4583 with a GF Score™ of 50/100 and a GF Value™ of 円87.77 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 708 Biotechnology companies, Chiome Bioscience ranks worse than 63.28% on this metric.
The historical rank and industry rank for Chiome Bioscience's Days Payable or its related term are showing as below:
TSE:4583'
s Days Payable Range Over the Past 10 Years
Min: 34.06 Med: 51.95 Max: 181.28
Current: 59.48
During the past 13 years, Chiome Bioscience's highest Days Payable was 181.28. The lowest was 34.06. And the median was 51.95.
TSE:4583's Days Payable is ranked worse than 63.28% of 708
companies
in the Biotechnology industry
Industry Median: 111.42
vs TSE:4583: 59.48
Chiome Bioscience's Days Payable
increased
from Jun. 2025 (55.56) to Jun. 2026 (80.91).
It may suggest that Chiome Biosciencedelayed paying its suppliers.
The historical data trend for Chiome Bioscience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Chiome Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Days Payable distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Chiome Bioscience's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience (TSE:4583) has a Days Payable of 80.91 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chiome Bioscience and its competitors. This is 56% above median its historical median of 51.95. Over the past decade, Chiome Bioscience's Days Payable has ranged from 34.06 to 181.28. According to the industry distribution chart, Chiome Bioscience ranks #448 out of 708 companies in the Biotechnology industry, placing it in the top 63.3%.
Is Chiome Bioscience's Days Payable too high?
Chiome Bioscience's current Days Payable of 80.91 is 56% above median its 10-year median of 51.95. Over the past 10 years, this metric has ranged from a low of 34.06 to a high of 181.28. The Biotechnology industry median Days Payable is 111.42. Chiome Bioscience's value of 80.91 is 27.4% below this industry median. Based on the distribution chart, Chiome Bioscience ranks #448 out of 708 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chiome Bioscience has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #448 out of 708 companies for Days Payable. This places Chiome Bioscience in the lower half of its industry. The industry median Days Payable is 111.42. Chiome Bioscience's value of 80.91 is 27.4% below this benchmark. Historically, Chiome Bioscience's own Days Payable has ranged from 34.06 to 181.28 over the past decade. While the company's 10-year median is 51.95 vs. the industry median of 111.42, Chiome Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.42, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chiome Bioscience's current Days Payable of 80.91 is 27.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chiome Bioscience and its competitors. For the Biotechnology industry, the median Days Payable is 111.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current Days Payable is 80.91, which is 56% above median its own 10-year median of 51.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Modestly Overvalued. The stock's GF Value™ is 円87.77, compared to a current price of 円97.00 — trading 10.5% above its estimated fair value. The current Days Payable is 80.91, which is 56% above median its 10-year median of 51.95 and 27.4% below the Biotechnology industry median of 111.42. Chiome Bioscience's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Days Payable is 80.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be overvalued.
The current stock price of 円97.00 is trading 10.5% above its estimated GF Value™ of 円87.77.
GuruFocus considers Chiome Bioscience to be Modestly Overvalued.
Key valuation signals for TSE:4583:
Days Payable: 80.91 (56% above median its 10-year median of 51.95)
GF Value™: 円87.77 vs. price of 円97.00 (10.5% above fair value)
Industry Position: 27.4% below the Biotechnology median (#448 of 708)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
50GF Score
Get the complete analysis for TSE:4583
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
